Navigation Links
Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM
Date:3/19/2012

FORT LAUDERDALE, Fla., March 19, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that Advent Financial, a leading financial analyst group focused on small and micro-cap companies, estimated next 5-year revenue for the Company at $42MM.  Advent has a very qualified team of research analysts with extensive experience at large investment banks including Bank of America, Goldman Sachs, and UBS Warburg.

As published in the analyst report in the projections and valuation section, Advent estimated next 5-year revenue for the Company at $42MM using the following assumptions: a) Company will steadily increase its distribution footprint by signing agreements with national pharmacy chains; b) Over the next five years, Azul Instant™ will be available at 35% of all retail outlets managed by the national pharmacy chains.  Agreements with traditional retailers will provide further upside to our revenue estimate; c) Average revenue per store will increase from $300/month in 2012 to $500/month by 2013.

To view the report in its entirety, please visit: http://www.adventfinancialinc.com/research/index.php under recent reports.

About Azul Instant™

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals to provide a safe and natural alternative for the millions of men suffering from erectile dysfunction.  The Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated.  Patients will now receive the NATURAL benefits of Azul Instant™ and unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects.  While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works as fast as 5 minutes.  Azul Instant™ can last for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects. 

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants
2. Leading Cardiovascular Organizations Release Credentialing Recommendations for Heart Valve Replacement Procedure
3. Qmed, the Leading Global MedTech Industry Resource, Partners with onTargetjobs to Provide Medical Device Professionals and Employers with Career Services Tool
4. Leading Industry Multinationals Participate in Medical Device Costa Rica Panel: "Developing a Strong Supplier Base"
5. Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Companys Market Leading Position
6. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
7. Leading Antitrust Senator Raises Serious Doubts About Proposed Express Scripts-Medco PBM Merger
8. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
9. Worlds Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event
10. Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
11. International Panel of Leading Bariatric Surgeons Reaches Consensus on Optimal Techniques for Laparoscopic Sleeve Gastrectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... ... ... BSI and Brenntag Canada have been appointed by Chr. Hansen as their ... fruits and beverage colorants effective November 1, 2016. , “The ... product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing Chr. Hansen will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
Breaking Medicine News(10 mins):